OncoCyte Corporation (OCX) News

OncoCyte Corporation (OCX): $2.67

0.02 (-0.74%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

F

Filter OCX News Items

OCX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

OCX News Highlights

  • For OCX, its 30 day story count is now at 3.
  • Over the past 27 days, the trend for OCX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • CMS, LAB and NOV are the most mentioned tickers in articles about OCX.

Latest OCX News From Around the Web

Below are the latest news stories about ONCOCYTE CORP that investors may wish to consider to help them evaluate OCX as an investment opportunity.

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

- Significant unmet need for regulated product in $2B US testing market - Opportunity for expedited pathway for kitted product in development IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays. The single-site process is a well-established pathway for Lab Developed Tests (LDTs) to seek regulatory approval. This move positions Oncocyte wi

Yahoo | December 6, 2023

OncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the Horizon

Strategic Focus on Upcoming Product Launches Amidst Tightened Cash Burn Management

Yahoo | November 9, 2023

Oncocyte Reports Third Quarter 2023 Financial Results

-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial re

Yahoo | November 9, 2023

Oncocyte to Announce Third Quarter 2023 Financial Results

Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ETIRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issu

Yahoo | November 3, 2023

Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the European Society of Organ Transplant (ESOT) conference.

Yahoo | September 18, 2023

Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C.

Yahoo | September 6, 2023

Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a positive coverage decision for the Company's VitaGraft Kidney™ diagnostic test, confirming that the test has met the criteria for coverage under MolDX: Molecular Testing for Solid Organ Allograft Rejection (L38568).

Yahoo | August 28, 2023

Oncocyte Reports Second Quarter 2023 Financial Results

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the second quarter of 2023, ended June 30, 2023.

Yahoo | August 10, 2023

Oncocyte Regains Compliance With Nasdaq Listing Requirements

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed.

Yahoo | August 9, 2023

Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference taking place on August 14-15th, 2023.

Yahoo | August 8, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!